Stox
30
Cohance Lifesciences Ltd.
NSE: COHANCE · Healthcare
₹433.55-3.44%06 Nov 2026
Ask the data
Instant answers about Cohance Lifesciences Ltd. — computed from its filings, no language modelMarket cap₹16,588 cr
Current price₹433.55
High / Low₹779 / ₹280
P/E156.1
P/B4.24
Book value₹102.2
ROE2.7%
ROCE3.3%
Debt / equity0.04
Dividend yield—
EPS (TTM)₹2.78
Face value₹1
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY20 | FY21 | FY22 | FY23 | FY26 | |
|---|---|---|---|---|---|
| Revenue | 834 | 1,010 | 1,320 | 1,340 | 2,269 |
| EBITDA | 385 | 440 | 579 | 567 | 427 |
| Operating margin | 46.2% | 43.6% | 43.9% | 42.3% | 18.8% |
| Interest | 23 | 9 | 6 | 5 | 37 |
| Depreciation | 24 | 32 | 39 | 48 | 187 |
| Profit before tax | 356 | 414 | 626 | 560 | 207 |
| Tax | 88 | 105 | 214 | 148 | 57 |
| Net profit | 317 | 362 | 0 | 411 | 179 |
| EPS ₹ | 24.91 | 14.23 | 17.83 | 16.16 | 4.69 |
| Operating cash flow | — | — | 330 | 451 | 368 |
| Capex | — | — | 75 | 286 | 220 |
| Dividend paid | — | — | 102 | 204 | 0 |
| Total assets | 1,173 | 1,474 | 1,830 | 1,966 | 5,730 |
| Equity | 845 | 1,181 | 1,527 | 1,735 | 3,911 |
Quarterly performance
last 24 quarters · ₹ crore| MAR '20 | JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | JUN '24 | SEP '24 | DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 185 | 238 | 237 | 275 | 259 | 264 | 301 | 392 | 364 | 339 | 278 | 354 | 369 | 348 | 231 | 220 | 231 | 258 | 307 | 549 | 556 | 545 | 619 | 422 |
| Operating profit | 77 | 112 | 98 | 138 | 94 | 115 | 122 | 186 | 157 | 151 | 100 | 147 | 169 | 167 | 98 | 65 | 80 | 104 | 118 | 112 | 121 | 95 | 99 | 1 |
| Operating margin | 41.9% | 47.0% | 41.5% | 50.2% | 36.2% | 43.4% | 40.5% | 47.5% | 43.2% | 44.5% | 35.9% | 41.5% | 45.8% | 48.0% | 42.4% | 29.6% | 34.6% | 40.4% | 38.3% | 20.4% | 21.8% | 17.5% | 15.9% | 0.3% |
| Other income | 5 | 6 | 0 | 5 | 3 | 6 | 5 | 65 | 17 | 11 | 11 | 13 | 11 | 11 | 20 | 14 | 18 | 14 | 16 | 14 | 16 | 6 | -2 | 12 |
| Interest | 7 | 3 | 3 | 3 | 2 | 2 | 1 | 1 | 2 | 1 | 0 | 1 | 2 | 1 | 0 | 1 | 2 | 2 | 3 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 7 | 7 | 8 | 9 | 8 | 9 | 9 | 11 | 10 | 12 | 12 | 12 | 12 | 13 | 12 | 13 | 13 | 17 | 20 | 45 | 44 | 47 | 51 | 50 |
| Profit before tax | 68 | 108 | 88 | 132 | 87 | 109 | 116 | 239 | 161 | 149 | 98 | 146 | 166 | 164 | 105 | 65 | 83 | 100 | 110 | 63 | 84 | 41 | 20 | -43 |
| Tax | 15 | 26 | 23 | 34 | 22 | 28 | 37 | 79 | 70 | 41 | 26 | 38 | 42 | 43 | 26 | 19 | 22 | 18 | 26 | 16 | 17 | 12 | 12 | 2 |
| Net profit | 74 | 92 | 74 | 114 | 83 | 105 | 97 | 160 | 0 | 0 | 72 | 0 | 124 | 0 | 80 | 47 | 0 | 82 | 83 | 49 | 74 | 37 | 20 | -24 |
| EPS ₹ | 5.83 | 7.19 | 2.91 | 4.46 | 3.27 | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 | 2.83 | 4.23 | 4.87 | 4.74 | 3.13 | 1.84 | 2.39 | 3.23 | 3.26 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
| Revenue YoY | — | — | — | — | 40.3% | 10.7% | 26.8% | 42.4% | 40.4% | 28.4% | -7.5% | -9.7% | 1.5% | 2.6% | -17.0% | -37.9% | -33.6% | 11.5% | 39.7% | 138.1% | 115.6% | 77.3% | — | -23.1% |
| Profit YoY | — | — | — | — | 12.1% | 14.8% | 30.9% | 40.9% | -100.0% | -100.0% | -25.7% | -100.0% | — | — | 10.4% | — | — | 3.3% | 77.3% | — | -9.9% | -55.7% | — | -149.3% |
Returns & margins
trailing-twelve-month, per quarter| DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 41.8% | 30.7% | 31.8% | 33.8% | 37.7% | 23.7% | 16.8% | 15.4% | 4.8% | 11.3% | 11.3% | 10.5% | 12.9% | 4.6% | 2.7% |
| ROCE | 40.0% | 32.1% | 32.2% | 34.2% | 42.2% | 39.0% | 41.4% | 41.0% | 35.1% | 31.3% | 32.1% | 29.6% | 25.5% | 6.0% | 3.3% |
| Net margin | 37.8% | 35.9% | 36.3% | 36.3% | 36.6% | 27.4% | 18.4% | 16.9% | 5.4% | 14.6% | 14.5% | 15.6% | 21.4% | 7.9% | 5.0% |
| EBITDA margin | 45.6% | 43.8% | 43.0% | 42.6% | 42.5% | 43.9% | 44.1% | 43.3% | 41.5% | 42.3% | 43.2% | 44.6% | 42.7% | 18.8% | 14.8% |
| Debt / equity | 0.22 | 0.12 | 0.12 | 0.12 | 0.12 | 0.06 | 0.06 | 0.06 | 0.06 | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 | 0.04 |
| Interest coverage | 25.09 | 38.39 | 42.61 | 57.14 | 94.24 | 101.40 | 120.81 | 139.80 | 105.48 | 104.08 | 113.03 | 109.92 | 96.80 | 6.56 | 4.00 |
| Asset turnover | 0.80 | 0.68 | 0.70 | 0.75 | 0.82 | 0.72 | 0.76 | 0.76 | 0.74 | 0.68 | 0.69 | 0.61 | 0.55 | 0.40 | 0.37 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '19‡ | MAR '20‡ | MAR '21‡ | MAR '22‡ | SEP '22 | MAR '23 | SEP '23 | SEP '24 | SEP '25 | MAR '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Share capital | 0 | 13 | 25 | 25 | 25 | 25 | 25 | 25 | 38 | 38 |
| Other equity / reserves | 590 | 832 | 1,155 | 1,502 | 1,478 | 1,710 | 1,910 | 1,953 | 3,749 | 3,873 |
| Total equity | 590 | 845 | 1,181 | 1,527 | 1,503 | 1,735 | 1,935 | 1,978 | 3,788 | 3,911 |
| Borrowings | 83 | 185 | 141 | 96 | 91 | 69 | 49 | 9 | 222 | 170 |
| Current liabilities | 158 | 200 | 220 | 210 | 216 | 159 | 112 | 238 | 631 | 646 |
| Non-current liabilities | 35 | 128 | 74 | 92 | 86 | 72 | 72 | 239 | 1,012 | 1,050 |
| Total assets | 783 | 1,173 | 1,474 | 1,830 | 1,806 | 1,966 | 2,120 | 2,506 | 5,568 | 5,730 |
| Property, plant & equipment | 268 | 353 | 437 | 531 | 591 | 584 | 572 | 652 | 1,763 | 1,990 |
| Capital work-in-progress | 111 | 102 | 96 | 30 | 87 | 165 | 172 | 241 | 357 | 173 |
| Investments | — | — | — | — | 444 | 536 | 770 | 751 | 454 | 529 |
| Inventories | 157 | 175 | 201 | 283 | 318 | 313 | 271 | 215 | 593 | 562 |
| Receivables | 148 | 117 | 102 | 236 | 111 | 111 | 137 | 184 | 590 | 681 |
| Cash & equivalents | 11 | 12 | 7 | 45 | 67 | 65 | 58 | 37 | 83 | 49 |
Cash flow
annual · ₹ crore · line = free cash flow| FY19‡ | FY20‡ | FY21‡ | FY22 | FY23 | FY26 | |
|---|---|---|---|---|---|---|
| Cash from operations | 50 | 407 | 383 | 330 | 451 | 368 |
| Cash from investing | -65 | -413 | -311 | -136 | -195 | -255 |
| Cash from financing | 26 | 7 | -76 | -156 | -236 | -165 |
| Capex | 57 | 103 | 111 | 75 | 286 | 220 |
| Free cash flow | -6 | 304 | 272 | 255 | 165 | 148 |
| Dividends paid | 23 | 77 | 25 | 102 | 204 | 0 |
Where the assets sit
Mar '26 · ₹ croreFixed assets (PPE)₹1,990 cr35%
CWIP₹173 cr3%
Investments₹529 cr9%
Inventories₹562 cr10%
Receivables₹681 cr12%
Cash & equivalents₹49 cr1%
Other assets₹1,745 cr30%
Peer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Cohance Lifesciences Ltd. | 16,588 | 433.55 | 156.1 | 4.24 | 2.7% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month-4.8%
6 months-10.6%
1 year-44.9%
3Y CAGR-8.8%
5Y CAGR-2.9%
10Y CAGR—
50-day avg₹451.98
200-day avg₹409.43
RSI (14)39
Compare Cohance Lifesciences Ltd. with
Onesource Specialty Pharma vs Cohance LifesciencesCaplin Point Laboratories vs Cohance LifesciencesSyngene International vs Cohance LifesciencesCohance Lifesciences vs Poly MedicureCohance Lifesciences vs Vijaya Diagnostic CentreCohance Lifesciences vs NATCO PharmaCohance Lifesciences vs Rainbow Childrens Medicare
FAQs
What is the share price of Cohance Lifesciences Ltd.?
Cohance Lifesciences Ltd. (COHANCE) closed at ₹433.55 on NSE on 06 Nov 2026.
What is the market cap of Cohance Lifesciences Ltd.?
₹16,588 crore at the latest close.
What is the P/E ratio of Cohance Lifesciences Ltd.?
156.1, on trailing-twelve-month earnings from its filings.
How fast is Cohance Lifesciences Ltd. growing?
Cohance Lifesciences Ltd.: revenue has compounded at 31.0% a year over three years; net profit at -20.9% a year. Latest-quarter revenue is down 23.1% year on year, profit down 149.3%.
How profitable is Cohance Lifesciences Ltd.?
On a trailing-twelve-month basis return on equity is 2.7%, return on capital employed 3.3%, operating margin 14.8%, net margin 5.0%.
How much debt does Cohance Lifesciences Ltd. have?
Cohance Lifesciences Ltd. is debt-free: debt to equity is 0.04 with borrowings of ₹170 cr against cash of ₹49 cr (balance sheet of 2026-03-31). Operating profit covers interest 4.0 times.
Financials parsed from Cohance Lifesciences Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '20, annual from FY20, balance sheet from Mar '19. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.
Cohance Lifesciences Ltd. · advanced chart